Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $22.60

Capricor Therapeutics Inc (NASDAQ:CAPR) has received a consensus recommendation of “Buy” from the five brokerages that are presently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have covered the stock in the last year is $22.60.

Several equities research analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, October 9th. Cantor Fitzgerald restated an “overweight” rating and issued a $8.00 target price on shares of Capricor Therapeutics in a research note on Friday, September 20th. Oppenheimer reiterated an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Finally, Maxim Group upped their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th.

Insider Buying and Selling at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the business’s stock in a transaction on Friday, September 20th. The shares were bought at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the transaction, the insider now owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 12.00% of the company’s stock.

Institutional Trading of Capricor Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CAPR. Vanguard Group Inc. increased its stake in Capricor Therapeutics by 17.2% during the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after purchasing an additional 200,499 shares in the last quarter. Renaissance Technologies LLC increased its stake in Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 84,350 shares in the last quarter. Marshall Wace LLP bought a new stake in Capricor Therapeutics during the 2nd quarter worth approximately $426,000. Rhumbline Advisers bought a new stake in Capricor Therapeutics during the 2nd quarter worth approximately $147,000. Finally, BNP Paribas Financial Markets bought a new stake in Capricor Therapeutics during the 1st quarter worth approximately $40,000. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Price Performance

Shares of Capricor Therapeutics stock opened at $19.58 on Friday. The firm has a market capitalization of $626.15 million, a PE ratio of -22.51 and a beta of 4.01. The company’s fifty day moving average price is $7.76 and its two-hundred day moving average price is $6.16. Capricor Therapeutics has a 52-week low of $2.68 and a 52-week high of $21.98.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The firm had revenue of $3.97 million during the quarter, compared to analyst estimates of $4.51 million. Analysts predict that Capricor Therapeutics will post -1.13 earnings per share for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.